Overview
- 4 inspections across 4 sites are on record.
- 5 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2018-09-18.
At a glance
Inspections
4
Sites
4
Observations
5
Career since
Feb 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Michael E. Thase, M.D. | 18 Sep 2018 | Human Drugs | |
| Delia Chaverri, M.D. | 22 Dec 2017 | Human Drugs | View 483 → |
| Cti Biopharma Inc | 15 Jun 2016 | Human Drugs | View 483 → |
| Acadia Pharmaceuticals, Inc | 17 Feb 2016 | Human Drugs | View 483 → |
Sites inspected
Michael E. Thase, M.D.Philadelphia, United States1 insp.
Delia Chaverri, M.D.Madrid, Spain1 insp.
Cti Biopharma IncSeattle, United States1 insp.
Acadia Pharmaceuticals, IncSan Diego, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Benton M Ketron1 shared
Sheri S Oliver1 shared
Ni A Khin1 shared
Romeo A De Claro1 shared
Lakecha N Lewis1 shared
Sunitha K Rajaram1 shared
Full investigator report
Get the verbatim findings behind Phillip D Kronstein's 5 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site